Your unrestricted view into eyecare conferences across the spectrum. Gain exclusive access to Ophthalmology Times Europe® expert-led conference coverage from major meetings throughout the year featuring articles, videos, and insights shared by prominent experts of the ophthalmic community
Congress of the ESCRS reaches milestone age
September 12th 2022Taking place from 16–20 September 2022, and following the success of last year’s congress, the 40th ESCRS will again be a face-to-face event but supported by a virtual conferencing platform that will allow the sessions to also be streamed.
Positive interim data in Phase 2 BEHOLD trial investigating UBX1325 in DMO patients
September 10th 202212-week interim results of BEHOLD, a proof-of-concept Phase 2a study investigating the candidate UBX1325, provides a positive outlook for a novel senolytic approach for previously-treated patients with diabetic macular oedema.
Fluid monitor utilises AI to identify, localise and quantify retinal fluid
September 7th 2022Eyecare specialists benefit from being able to monitor their patients long term for optimised and personalised treatment regimens, as well as having access to a more efficient workflow and one which enables them to see more patients.
Multicentre Phase 3 clinical trial using AI in nAMD identifies, measures fluid volumes in real time
September 6th 2022According to Dr Gregor S. Reiter, the results from the multicentre Phase 3 clinical trial demonstrated that fluid volumes in patients with nAMD can be precisely identified, localised and measured in real-time using artificial intelligence.
First analysis of gene therapy for RPE65 inherited retinal dystrophies shows good safety, efficacy
September 3rd 2022At the 1-month evaluation, the full-field stimulus threshold had median decrease of -33.2 decibels (dB) (-33.7; -19.8) dB, which remained stable until the last assessment. Visual fields and visual acuity did not change significantly.
RGX-314 provided 2-Step or more improvement in diabetic severity in Phase 2 Altitude study analysis
September 2nd 2022The Phase 2 Altitude study is an open-label, randomized, controlled, dose-escalation evaluation of RGX-314, evaluating the efficacy, safety, and tolerability of suprachoroidal delivery of RGX-314 in patients with moderately severe/severe non-proliferative diabetic retinopathy or mild proliferative diabetic retinopathy.
Hair cortisol may act as molecular biomarker for retinitis pigmentosa patients
September 1st 2022Patients with retinitis pigmentosa experience greater levels of stress and anxiety than individuals in the general population and that the level of stress can be measured easily and non-invasively in hair.
EURETINA celebrates women in retina
August 28th 2022The stated core foundation of the Women in Retina program is that “the best innovations happen when diverse people with different perspectives collaborate.” The program will help ESRS harness these perspectives and challenge the way things are done and allow for them to be done better.
ASRS 2022 in review: New data on DMO, AMD presented at this year's meeting
July 19th 2022The American Society of Retina Specialists held its 40th Annual Meeting in New York, New York, United States, from 13-16 July, 2022. While data was presented for all topics in retina, new revelations in age-related macular degeneration, diabetic retinopathy, and diabetic macular oedema dominated the conversation.